|
ISRCTN
|
ISRCTN66395033
|
|
ClinicalTrials.gov identifier
|
|
|
Public title
|
The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin beta
|
|
Scientific title
|
|
|
Acronym
|
N/A
|
|
Serial number at source
|
ESA-2
|
|
Study hypothesis
|
That treating patients with anaemia in diabetic nephropathy to a higher haemoglobin target range decreases rate of decline of renal function, requirement for dialysis, doubling of creatinine and death.
|
|
Ethics approval
|
Applied for to the East London and the City Health Authority Reserach Ethics Committee One - expecting to go to Ethics meeting in early November 2006.
|
|
Study design
|
Randomised, controlled, open trial
|
|
Countries of recruitment
|
United Kingdom
|
|
Disease/condition/study domain
|
Anaemia in diabetic nephropathy
|
|
Participants - inclusion criteria
|
1. Male and female patients with diabetic nephropathy and chronic kidney disease III and IV
2. Age more than 18 years and less than 80 years
3. Haemoglobin less than 11.5 g/dl
|
|
Participants - exclusion criteria
|
1. Current treatment with an erythropoiesis-stimulating agent (ESA)
2. Uncontrolled hypertension
3. Congestive cardiac failure
4. History of seizures
5. History of thrombotic episodes
6. Pregnancy
7. Lactation
8. Presence of systemic disease, infection or inflammatory conditions
9. Hepatic insufficiency
10. Active hepatitis
11. Uncontrolled hypothyroidism
12. Chronic alcoholism
13. Known hypersensitivity to the active substance in the cartridge or benzoic acid
14. Known sensitivity to epoetin beta
|
|
Anticipated start date
|
01/12/2006
|
|
Anticipated end date
|
30/11/2009
|
|
Status of trial
|
Ongoing
|
|
Patient information material
|
|
|
Target number of participants
|
160
|
|
Interventions
|
All patients should be iron replete (i.e. ferritin 0.1 or Tsats 0.2%) before randomisation. Participants will be given intravenous (IV) iron to replete iron stores if required before randomisation.
Participants will be randomised to two target ranges of haemoglobin on a 1:1 basis. Target ranges:
1. Hb 10.5 - 12 g/dl
2. Hb 12.1 - 13.5 g/dl
Participants will be treated with Epoetin Beta subcutaneously, if required, to maintain their haemoglobin within the target group. This will be a starting dose of 50 units/kg/week given once a week. Dose will be titrated on a monthly basis to start with, and then modified according to response (total dose 720 units/kg/week). Participants will be treated for three years.
|
|
Primary outcome measure(s)
|
1. Rate of decline of renal function as determined by estimated glomerular filtration rate (GFR)
2. Composite end-point of:
2.1. Doubling of creatinine
2.2. Reaching end-stage renal failure
2.3. Death
|
|
Secondary outcome measure(s)
|
1. Change in left ventricular hypertrophy as measured on echocardiogram
2. Change in intimal and medial wall thickness as determined by intimal thickness and flow dependant vasodilation as determined by ultrasound
3. Change in functional quality of life scores
4. Change in markers of endothelial dysfunction
5. Change of markers of tubular damage in the urine
|
|
Sources of funding
|
Salary of research doctor funded through the hospital Research and Develpment Department by Roche Pharmaceuticals ( ML20597) (UK)
|
|
Trial website
|
|
|
Publications
|
|
|
Contact name
|
Prof
Magdi
Yaqoob
|
|
Address
|
Department of Kidney and Tranpslant Medicine
West Wing, Basement
Royal London Hospital
Whitechapel
|
|
City/town
|
London
|
|
Zip/Postcode
|
E1 1BB
|
|
Country
|
United Kingdom
|
|
Sponsor
|
Barts and the London NHS Trust (UK)
|
|
Address
|
Research and Development Office
3rd Floor Rutland House
42-46 New Road
Whitechapel
|
|
City/town
|
London
|
|
Zip/Postcode
|
E1 2AX
|
|
Country
|
United Kingdom
|
|
Sponsor website:
|
http://www.bartsandthelondon.org.uk/
|
|
Date applied
|
17/10/2006
|
|
Last edited
|
02/09/2008
|
|
Date ISRCTN assigned
|
04/12/2006
|